GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

GlaxoSmithKline ( (GSK)) has provided an update ... Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with ...

More about GlaxoSmithKline GSK is a global biopharmaceutical company dedicated to combining science, technology, and talent to advance healthcare. It has a leading respiratory portfolio and is ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

kerala lottery kerala lottery kerala lottery The first oral drug for SMA! Roche's Evrysdi has been approved for marketing in Japan and has entered the review stage in China A village doctor was fined ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

INR:4990. lucky teen patti apk The annual salary of CEOs of giants such as Gilead and Johnson & Johnson exceeds 20 million, but it pales in comparison with t ...

INR:5421. dog street photo GlaxoSmithKline's Nucala's third indication received priority review by the US FDA! Eli Lilly's Emgality reduces total pain burden in ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

INR:8213. sun rummy Outpatient coordination: an important step for payers to promote medical service reform GlaxoSmithKline's Nucala's third indication received priorit ...

INR:4915. raja rummy Another new application for ICOS receptor agonist with extremely fast global development progress has been reported for clinical trials in China G ...